Cytokine 2021 June 19 [Link] Loredana Urso, Micol Silic-Benussi, Alice Boscolo, Martina Lorenzi, Laura Bonanno, Francesca Lunardi, Valentina Guarneri, Fiorella Calabrese, Federico Rea, PierFranco Conte, Giulia Pasello Abstract Background: No data on circulating biomarkers for the prognostic stratification of Malignant Pleural Mesothelioma (MPM) patients are available. We prospectively explored the prognostic role of circulating monocyte…

Read More

International Journal of Hyperthermia 2021 [Link] Parisa Malekzadeh, Meghan Good, Marybeth S Hughes Abstract Introduction: Malignant peritoneal mesothelioma (MPM) is a lethal cancer, with approximately 2% of diagnoses occurring in patients less than 40 years of age. The purpose of this study is to report the only long-term follow up and survival of pediatric patients…

Read More

Drugs 2021 June [Link] Wanyuan Cui, Sanjay Popat Abstract Immune checkpoint inhibitors (ICI) have shown important but variable efficacy in mesothelioma despite a lack of strong biological rationale. Initial trials assessed ICI monotherapy in patients with relapsed mesothelioma, with objective response rates (ORR) between 4.5 and 29%, median progression-free survival (PFS) between 2.5-6.2 months, and…

Read More

World Journal of Surgical Oncology 2021 June 5 [Link] Suryanarayana Deo, Mukurdipi Ray, Babul Bansal, Sandeep Bhoriwal, Sushma Bhatnagar, Rakesh Garg, Nishkarsh Gupta, Atul Sharma, Lalit Kumar, Sanjay Thulkar, Ekta Dhamija, Sandeep Mathur, Prasenjit Das Abstract Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has recently emerged as a viable management option for peritoneal…

Read More

Journal of Translational Medicine 2021 May 31 [Link] Vilde Drageset Haakensen, Anna K Nowak, Espen Basmo Ellingsen, Saima Jamil Farooqi, Maria Moksnes Bjaanæs, Henrik Horndalsveen, Tine Mcculloch, Oscar Grundberg, Susana M Cedres, Åslaug Helland Abstract Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumour. For patients with inoperable disease, few treatment options are…

Read More

Cell Death Discovery 2021 May 28 [Link] Surein Arulananda, Megan O’Brien, Marco Evangelista, Laura J Jenkins, Ashleigh R Poh, Marzena Walkiewicz, Trishe Leong, John M Mariadason, Jonathan Cebon, Srividya B Balachander, Justin R Cidado, Erinna F Lee, Thomas John, Walter D Fairlie Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with treatment limited to…

Read More

Journal of Thoracic Disease 2021 April [Link] Sven Oliver Schumann, Gregor Kocher, Fabrizio Minervini Abstract The malignant pleural mesothelioma is a very aggressive tumor which is arising from mesothelial cells and is associated with asbestos exposure. It is a heterogeneous cancer that shows a complex pattern of molecular changes, including genetic, chromosomic, and epigenetic abnormalities.…

Read More

Annals of Translational Medicine 2021 April [Link] Caihua Xu, Yufeng Hu, Bin Chen, Dapeng Li, Rongrui Liang, Meng Shen, Mengyao Wu, Min Tao Abstract Background: Malignant pleural mesothelioma (MPM) chemoresistance remains a challenge to oncologists. In our previous study, we demonstrated that the aberrant expression of metastasis-associated gene 1 (MTA1) is associated with carcinogenesis and…

Read More

Lung Cancer 2021 June [Link] Frédéric Larose, Nicholas Quigley, Yves Lacasse, Simon Martel, Loïc Lang-Lazdunski Abstract Objectives: Medical management based on palliative chemotherapy is currently the standard of care in malignant pleural mesothelioma (MPM). Median survival of 12-16 months has been reported with modern chemotherapy regimens with or without anti-angiogenic agents. Multimodality therapy incorporating cytoreductive…

Read More

Frontiers in Oncology 2021 April 20 [Link] Oscar Arrieta, Wendy Muñoz-Montaño, Sae Muñiz-Hernández, Saul Campos, Rodrigo Catalán, Herman Soto-Molina, Silvia Guzmán Vázquez, Osvaldo Díaz-Álvarez, Victor Martínez-Pacheco, Jenny G Turcott, Maritza Ramos-Ramírez, Luis Cabrera-Miranda, Feliciano Barrón, Andrés F Cardona Abstract Background: Malignant pleural mesothelioma (MPM) is rare and aggressive neoplasia, with a poor prognosis; furthermore, the…

Read More